Clinical Trial Update: Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the reverse remodeling effects of the investigational drug CDR132L in patients with heart failure with preserved ejection fraction and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• CDR132L

Snippet

Sponsor: Cardior Pharmaceuticals GmbH | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: WITHDRAWN